USE OF CANNABIDIOL (CBD) FOR CANINE OSTEOARTHROSIS
Abstract
The Cannabis sativa plant is made up of a wide variety of active ingredients, which are called cannabinoids. There are 3 different types of cannabinoids: endocannabinoids, phytocannabinoids or herbal cannabinoids and synthetic cannabinoids.
This study focuses on the development of CBD, as it is a product that produces minimal or no psychoactive effects and has no toxicity to animals.
The vast majority of animals have an endocannabinoid system. This system consists of endogenous agonists and their receptors. This endocannabinoid system is also physiologically involved in the regulation of analgesia, learning, locomotor activity, anxiety, appetite, gastrointestinal motility, immune control and cardiovascular function.
CBD acts on a multitude of receptors in the body, producing a wide range of therapeutic actions.
Osteoarthrosis is an autodegenerative joint disease for which pain is the main clinical sign. Currently, the pharmacological management of OA may not produce adequate analgesia and may have undesirable effects.
The main objective of this study was to determine whether CBD could be an alternative in the treatment of OA or whether it could be used together in a multimodal treatment. To this end, five different articles were chosen.
The results of the studies showed that CBD significantly reduced the sensation of pain and improved quality of life. Secondary clinical signs were not observed when administering CBD, except from an increase in alkaline phosphatase which could cause liver damage.
The conclusions that can be drawn from this study are that CBD is a product with great therapeutic potential, minimal effective dose and minimal adverse effects. It proves to be a very complete drug, which needs further studies to be used more widely and without risk.
Downloads
References
Bloomfield, M. A. P., Hindocha, C., Green, S. F., Wall, M. B., Lees, R., Petrilli, K., Costello, H., Ogunbiyi, M. O., Bossong, M. G., & Freeman, T. P. (2019). The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacology & Therapeutics, 195, 132–161. https://doi.org/10.1016/J.PHARMTHERA.2018.10.006
Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017). Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacology 2018 43:1, 43(1), 142–154. https://doi.org/10.1038/npp.2017.209
Brioschi, F. A., di Cesare, F., Gioeni, D., Rabbogliatti, V., Ferrari, F., D’urso, E. S., Amari, M., & Ravasio, G. (2020). Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: Effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals, 10(9), 1–14. https://doi.org/10.3390/ani10091505
de Briyne, N., Holmes, D., Sandler, I., Stiles, E., Szymanski, D., Moody, S., Neumann, S., & Anadón, A. (2021). Cannabis, Cannabidiol Oils and Tetrahydrocannabinol—What Do Veterinarians Need to Know? Animals 2021, Vol. 11, Page 892, 11(3), 892. https://doi.org/10.3390/ANI11030892
Deabold, K. A., Schwark, W. S., Wolf, L., & Wakshlag, J. J. (2019). Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. Animals, 9(10). https://doi.org/10.3390/ani9100832
Dhital, S., Stokes, J. v., Park, N., Seo, K. S., & Kaplan, B. L. F. (2017). Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation. Cellular Immunology, 312, 25–34. https://doi.org/10.1016/j.cellimm.2016.11.006
D’Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. te, Braley, G., Gueorguieva, R., & Krystal, J. H. (2004). The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology 2004 29:8, 29(8), 1558–1572. https://doi.org/10.1038/sj.npp.1300496
ElSohly, M. A., Gul, W., Wanas, A. S., & Radwan, M. M. (2014). Synthetic cannabinoids: Analysis and metabolites. Life Sciences, 97(1), 78–90. https://doi.org/10.1016/J.LFS.2013.12.212
Francesc Pla Juncá. (2022). Farmacología de la interacción del tetrahidrocannabinol y cannabidiol en voluntarios sanos. Departamento de farmacología, terapéutica y toxicología, universidad autónoma de Barcelona.
Gamble, L. J., Boesch, J. M., Frye, C. W., Schwark, W. S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E. S., & Wakshlag, J. J. (2018). Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Frontiers in Veterinary Science, 5. https://doi.org/10.3389/fvets.2018.00165
Greb, A., & Puschner, B. (2018). Cannabinoid treats as adjunctive therapy for pets: gaps in our knowledge. Https://Doi.Org/10.1080/24734306.2018.1434470, 2(1), 10–14. https://doi.org/10.1080/24734306.2018.1434470
Gugliandolo, E., Licata, P., Peritore, A. F., Siracusa, R., D’amico, R., Cordaro, M., Fusco, R., Impellizzeri, D., di Paola, R., Cuzzocrea, S., Crupi, R., & Interlandi, C. D. (2021). Effect of cannabidiol (Cbd) on canine inflammatory response: An ex vivo study on lps stimulated whole blood. Veterinary Sciences, 8(9). https://doi.org/10.3390/vetsci8090185
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., & Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacological Reviews, 54(2), 161–202. https://doi.org/10.1124/PR.54.2.161
Kogan, L. R. (2020). The Use of Cannabidiol-Rich Hemp Oil Extract to Treat Canine Osteoarthritis-Related Pain: A Pilot Study The frequency and type of vehicular restraint of dogs within the UK, USA and Australia View project Emotional support animals View project. https://www.researchgate.net/publication/339698157
Landa, L., Sulcova, A., & Gbelec, P. (2016). The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Http://Agriculturejournals.Cz/Doi/10.17221/8762-VETMED.Html, 61(3), 111–122. https://doi.org/10.17221/8762-VETMED
Maida, V., & Daeninck, P. J. (2016). A User’s Guide to Cannabinoid Therapies in Oncology. Current Oncology 2016, Vol. 23, Pages 398-406, 23(6), 398–406. https://doi.org/10.3747/CO.23.3487
Morris, E. M., Kitts-Morgan, S. E., Spangler, D. M., Gebert, J., Vanzant, E. S., McLeod, K. R., & Harmon, D. L. (2021). Feeding Cannabidiol (CBD)-Containing Treats Did Not Affect Canine Daily Voluntary Activity. Frontiers in Veterinary Science, 8. https://doi.org/10.3389/fvets.2021.645667
Morrow, L., & Belshaw, Z. (2020). Does the addition of cannabidiol alongside current drug treatments reduce pain in dogs with osteoarthritis? In Veterinary Record (Vol. 186, Issue 15, pp. 493–494). British Veterinary Association. https://doi.org/10.1136/vr.m1594
Nichols, J. M., Kummari, E., Sherman, J., Yang, E. J., Dhital, S., Gilfeather, C., Yray, G., Morgan, T., & Kaplan, B. L. F. (2021). CBD Suppression of EAE Is Correlated with Early Inhibition of Splenic IFN-γ + CD8+ T Cells and Modest Inhibition of Neuroinflammation. Journal of Neuroimmune Pharmacology, 16(2), 346–362. https://doi.org/10.1007/s11481-020-09917-8
Papagianni, E. P., & Stevenson, C. W. (2019). Cannabinoid Regulation of Fear and Anxiety: an Update. Current Psychiatry Reports, 21(6), 1–10. https://doi.org/10.1007/S11920-019-1026-Z/METRICS
Pertwee, R. G. (2012). Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 367(1607), 3353–3363. https://doi.org/10.1098/RSTB.2011.0381
Potschka, H., Bhatti, S. F. M., Tipold, A., & McGrath, S. (2022). Cannabidiol in canine epilepsy. Veterinary Journal. https://doi.org/10.1016/j.tvjl.2022.105913
Silver, R. J. (2019). The Endocannabinoid System of Animals. Animals 2019, Vol. 9, Page 686, 9(9), 686. https://doi.org/10.3390/ANI9090686
Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018). A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs, 32(11), 1053–1067. https://doi.org/10.1007/S40263-018-0578-5/TABLES/9
Verrico, C. D., Wesson, S., Konduri, V., Hofferek, C. J., Vazquez-Perez, J., Blair, E., Dunner, K., Salimpour, P., Decker, W. K., & Halpert, M. M. (2020). A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain, 161(9), 2191–2202. https://doi.org/10.1097/j.pain.0000000000001896
Wallace, J. E., Kogan, L. R., Carr, E. C. J., & Hellyer, P. W. (2020). Motivations and expectations for using cannabis products to treat pain in humans and dogs: a mixed methods study. Journal of Cannabis Research 2020 2:1, 2(1), 1–12. https://doi.org/10.1186/S42238-020-00045-X
Yu, C. H. J., & Rupasinghe, H. P. V. (2021). Cannabidiol-based natural health products for companion animals: Recent advances in the management of anxiety, pain, and inflammation. In Research in Veterinary Science (Vol. 140, pp. 38–46). Elsevier B.V. https://doi.org/10.1016/j.rvsc.2021.08.001
Zou, S., & Kumar, U. (2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences, 19(3). https://doi.org/10.3390/IJMS19030833
Copyright (c) 2023 Servicio de Publicaciones, University of Murcia (Spain)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons Attribution 4.0
The works published in this journal are subject to the following terms:
1. The Publications Service of the University of Murcia (the publisher) retains the property rights (copyright) of published works, and encourages and enables the reuse of the same under the license specified in paragraph 2.
© Servicio de Publicaciones, Universidad de Murcia, 2019
2. The works are published in the online edition of the journal under a Creative Commons Attribution-NonCommercial 4.0 (legal text). You can copy, use, distribute, transmit and publicly display, provided that: i) you cite the author and the original source of publication (journal, editorial and URL of the work), ii) are not used for commercial purposes, iii ) mentions the existence and specifications of this license.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
3. Conditions of self-archiving. Is allowed and encouraged the authors to disseminate electronically pre-print versions (version before being evaluated and sent to the journal) and / or post-print (version reviewed and accepted for publication) of their works before publication, as it encourages its earliest circulation and diffusion and thus a possible increase in its citation and scope between the academic community. RoMEO Color: Green.
